이뮤니티바이오(IBRX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $8.48 (+0.24%), 시가총액 $8.09B, 52주 최저~최고 $1.98 ~ $11.55.
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for
이뮤니티바이오의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
이뮤니티바이오의 현재 주가는 $8.48 (+0.24%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
이뮤니티바이오의 시가총액은 약 $8.09B입니다.
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable